
INTerpath-001's Full Phase 3 Data Are In: What Moderna and Merck's Personalized Melanoma Vaccine Actually Showed
7 min readFull ESMO data show the personalized mRNA vaccine plus pembrolizumab cut melanoma recurrence risk 42% — smaller than Phase 2b, with overall survival still immature.










